BioReference After the Asset Sales: Can 4Kscore and the Regional Core Reach Profitability?
After the two Labcorp sales, BioReference is left with a concentrated clinical base in New York and New Jersey, a national 4Kscore franchise, and correctional healthcare services. The cost reset is real, but without disposal gains the core was still loss-making in 2025, which makes 2026 look like a proof year rather than a completed turnaround.
After the main article framed OPKO as a leaner company with a more expensive capital structure, this continuation isolates only the BioReference question that still matters: after the two Labcorp sales, is there now a diagnostics business that can stand on its own, or only a smaller platform with a smaller loss.
The answer is not binary yet. The reset is real. The cost base is lower, the footprint is narrower, 4Kscore is still growing, and management now explicitly defines profitability as a near-term goal. Profitability itself is still not here. Diagnostics finished 2025 with reported operating income of $21.3 million, but that number includes a $101.6 million gain on the oncology asset sale. Without that disposal gain, the core still posted an operating loss of about $80.3 million.
That is still a major improvement from 2024, but that is exactly the point. Post-Labcorp BioReference is no longer a story about rebuilding a broad national lab network. It is a narrower test: can a regional clinical base in New York and New Jersey, together with 4Kscore and correctional healthcare services, generate enough gross profit to cover what remains of the platform.
Four points sharpen that test immediately:
- The two Labcorp sales represented about $200 million of annual revenue before the divestitures, so 2026 starts from a much smaller base.
- BioReference fell to about 1,373 full-time employees at the end of 2025, down from about 3,300 before the restructurings, and closed laboratory facilities in California, Texas, Florida, and Maryland.
- Even inside the continuing business, 2025 still included a $10.2 million decline from lower clinical test volume, so the story is not only “sold assets, lost revenue” but also a core that has not yet shown a clean return to growth.
- 4Kscore added roughly $3.2 million of revenue and grew by more than 13%, but that contribution is still far smaller than the core loss after stripping out disposal gains.
What BioReference Actually Looks Like Now
The most important step in reading the new BioReference is understanding what the company is no longer trying to be. It first sold clinical diagnostics, reproductive health, and women’s health testing outside New York and New Jersey, then sold the oncology diagnostics business. What remains is not a broad national lab model. It is a much tighter structure: clinical and women’s health testing in New York and New Jersey, a national 4Kscore franchise, and correctional healthcare services.
That distinction matters because it changes the profitability threshold. This business no longer depends on rebuilding a full national footprint. It depends on two narrower and much more measurable things: preserving enough density in the New York and New Jersey core, and turning 4Kscore from a high-quality growth product into a much more meaningful profit engine.
The segment balance sheet also shows how deep the shrinkage has been. Diagnostics assets fell to $349.1 million at year-end 2025 from $493.9 million a year earlier, and goodwill fell to $163.4 million from $219.7 million. That is not just portfolio cleanup. It is evidence that the company is no longer being tested on whether it can carry a large platform, but on whether it can earn acceptable economics from a much smaller one.
4Kscore Is the Differentiated Asset, but It Is Not Enough Yet
It is easy to see why 4Kscore has become central to the story. In 2025 the test received a label expansion that allows use without DRE information, and the company explicitly notes that more than 90% of PSA screening tests in the U.S. are ordered by primary care providers, who may not routinely perform DRE. That broadens the potential user base and lowers adoption friction. In addition, 4Kscore has a Category I CPT code, positive Medicare coverage through Novitas, and positive coverage from several private and commercial payors. This is not a promising product with no reimbursement path. It is a differentiated franchise with real clinical and commercial anchors.
The 2025 results partially confirm that. 4Kscore revenue increased by more than 13%, or about $3.2 million year over year. In the context of a smaller BioReference, that matters because it comes from a more differentiated product than routine testing. But the scale still needs perspective. In the same year, continuing operations lost $10.2 million from lower clinical volume, and the adjusted core remained deeply loss-making.
So 4Kscore is already proving that BioReference still owns an asset worth building around. It is not yet proving that it is large enough to carry the entire segment to profitability by itself. What is missing is not another reminder that the test is good. What is missing is proof that its growth, together with better reimbursement and stability in the regional base, can actually cover a cost structure that still remains too heavy.
The Real Profitability Test Is Not the Reported Number
The most misleading figure in this segment is the reported operating result. On paper, diagnostics moved from an operating loss of $24.1 million in 2024 to operating income of $21.3 million in 2025. At first glance, that looks close to breakeven. That is the wrong read. Both numbers include gains on assets sold to Labcorp, $121.5 million in 2024 and $101.6 million in 2025.
Strip those gains out and the picture becomes much more useful: an operating loss of about $145.6 million in 2024 versus about $80.3 million in 2025. That is a sharp improvement, but it also shows that the heavy lifting is not finished. BioReference did not move from loss to profit. It moved from a very large loss to a smaller loss inside a much smaller business.
The numbers underneath that line do deserve credit. Cost of revenue fell by $94.8 million, selling, general and administrative expense fell by $75.9 million, and the company ties that to both the disappearance of sold operations and to reductions in headcount, rent, technology, communications, raw materials, and reference lab testing. This is not cosmetic cleanup.
But gross profit dollars still fell to $62.9 million from $78.6 million a year earlier. That may be the single most important number in this continuation. To reach profitability, BioReference has to do more than become leaner. It has to generate enough gross profit after the divestitures to carry what is left of the fixed-cost base. In 2025 that gap narrowed, but it did not close.
| Metric | 2024 | 2025 | What it says |
|---|---|---|---|
| Diagnostics revenue | 480.7 | 370.3 | A large part of the decline was deliberate, but not all of it |
| Gross profit | 78.6 | 62.9 | The dollar gross-profit pool is smaller even after restructuring |
| SG&A | 205.2 | 129.3 | The cost reset is real and material |
| Reported operating income | (24.1) | 21.3 | It looks like a turnaround, but includes the sale gain |
| Operating income without disposal gains | (145.6) | (80.3) | Major improvement, still not profitability |
What the 2025 Pattern Says About 2026
This is where extrapolation gets dangerous. At the company-wide level, the third quarter of 2025 was the only quarter with positive net income, $21.6 million. That was also the quarter in which the oncology sale closed. In the fourth quarter, after the sale was already behind the company, revenue stayed relatively similar at $148.5 million versus $151.7 million, but the bottom line moved back to a net loss of $31.3 million.
That does not provide a full segment read, so it should not be stretched too far. But it is still a useful warning against annualizing the disposal quarter as if it were the new clean run-rate. If anything, it says the opposite: after the sale closed, the company entered 2026 still needing to prove that the smaller operating model works without more one-off help.
That is why 2026 looks like a proof year for BioReference. Not a year of rebuilding a network, and not a year of nostalgia for old scale, but a year in which three things have to happen together: 4Kscore has to keep growing, the New York and New Jersey core has to stop losing volume, and the cost gains have to hold even after the one-time restructuring moves are exhausted.
Bottom Line
After the Labcorp sales, BioReference has become easier to understand, but not a business that has already proved self-sustaining profitability. There is a real reset here: a smaller operating base, a differentiated asset in 4Kscore, and a clearer focus on the markets where the company still operates. That is the constructive part, and it is real.
The practical constraint is still the same: the core does not yet fund itself. In 2025, 4Kscore and better reimbursement helped, but not enough to offset lower volume in continuing operations and the operating loss that remains once disposal gains are stripped out. So the key question is no longer whether the sales cleaned up the story. It is whether the business that remains can generate profit without having to sell something else on the way there.
This is no longer a question about BioReference’s past footprint. It is a question about whether 4Kscore and the remaining regional core are actually enough to carry the business on their own.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.